Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 9, 2021
Tools & Techniques
What DeepMind’s leap means for structure-based drug developers
AlphaFold’s biggest impact on biopharma will be opening more targets to structure-based approaches, more quickly
BioCentury | Jul 29, 2020
Emerging Company Profile
Bright Peak synthesizing proteins like they’re small molecules with $35M from Versant
Bright Peak brings a chemical synthesis approach to the modified IL-2 arena
BioCentury | Jan 9, 2020
Clinical News
ADC’s loncastuximab data could clear path for BLA, IPO filing
B cell lymphoma data give ADC Therapeutics dry powder as it prepares to mount a second IPO attempt
BioCentury | Jul 18, 2019
Emerging Company Profile
Neoleukin emerges with a de novo approach to improving biologics
Why Neoleukin is making biologics from scratch rather than fine-tuning existing ones
Items per page:
1 - 6 of 6